- Home
- CNK vs MIRM Comparison
CNK vs MIRM Comparison
Compare CNK & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNK
- MIRM
- Stock Information
- Founded
- CNK 1984
- MIRM 2018
- Country
- CNK United States
- MIRM United States
- Employees
- CNK N/A
- MIRM N/A
- Industry
- CNK Movies/Entertainment
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- CNK Consumer Discretionary
- MIRM Health Care
- Exchange
- CNK Nasdaq
- MIRM Nasdaq
- Market Cap
- CNK 3.3B
- MIRM 3.7B
- IPO Year
- CNK 2007
- MIRM 2019
- Fundamental
- Price
- CNK $27.55
- MIRM $72.69
- Analyst Decision
- CNK Strong Buy
- MIRM Strong Buy
- Analyst Count
- CNK 10
- MIRM 11
- Target Price
- CNK $35.30
- MIRM $82.82
- AVG Volume (30 Days)
- CNK 3.1M
- MIRM 593.2K
- Earning Date
- CNK 11-05-2025
- MIRM 11-04-2025
- Dividend Yield
- CNK 1.17%
- MIRM N/A
- EPS Growth
- CNK N/A
- MIRM N/A
- EPS
- CNK 1.11
- MIRM N/A
- Revenue
- CNK $3,153,000,000.00
- MIRM $471,794,000.00
- Revenue This Year
- CNK $7.03
- MIRM $53.14
- Revenue Next Year
- CNK $7.63
- MIRM $19.83
- P/E Ratio
- CNK $24.60
- MIRM N/A
- Revenue Growth
- CNK 9.70
- MIRM 53.66
- 52 Week Low
- CNK $23.12
- MIRM $36.88
- 52 Week High
- CNK $36.28
- MIRM $78.55
- Technical
- Relative Strength Index (RSI)
- CNK 43.65
- MIRM 55.55
- Support Level
- CNK $27.84
- MIRM $71.04
- Resistance Level
- CNK $30.91
- MIRM $73.50
- Average True Range (ATR)
- CNK 1.08
- MIRM 2.74
- MACD
- CNK -0.31
- MIRM 0.33
- Stochastic Oscillator
- CNK 8.27
- MIRM 78.35
About CNK Cinemark Holdings Inc Cinemark Holdings Inc.
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.